Share

    


In This Section

Home / Blurb / Discussion List

FDA Restricts Use of Keytruda and Tecentriq for Urothelial Cancer

Jun 21, 2018, 10:00 AM
URL:
On June 20, 2018, the FDA announced that it was restricting the use of Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.

This restriction results from decreased survival associated with the use of Keytruda or Tecentriq as monotherapy compared to platinum-based chemotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).

Read the full FDA announcement here.

Posted 6/21/2018

Leave a comment